Brief: C-Rad And Accuray Sign Agreement To Enhance Radixact System Breast Cancer Treatment Capabilities
Oct 4 (Reuters) - Accuray Inc ARAY.O :
* C-RAD AND ACCURAY SIGN AGREEMENT TO ENHANCE RADIXACT®
SYSTEM
BREAST CANCER TREATMENT CAPABILITIES
* EVELOPMENT WORK WILL COMMENCE BEFORE END OF 2021
* FIRST INTERFACE LINKING CATALYST TECHNOLOGY AND RADIXACT
SYSTEM
ANTICIPATED TO BE MADE AVAILABLE IN MID-2022.
Source text for Eikon: ID:nMFN6wrBRQ
Further company coverage: ARAY.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Accuray Incorporated
See all newsBrief: Accuray And Raysearch Agree To Collaboration Integrating Raystation Software
Accuray Q4 revenue falls as tariff concerns, geopolitical tensions weigh on demand
Accuray Incorporated reports results for the quarter ended June 30 - Earnings Summary
Accuray Incorporated expected to post a loss of 10 cents a share - Earnings Preview
Brief: Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments